Peptide

Tesamorelin

GHRH(177-191) analog

Evidence TierBWADA PROHIBITED

tuneTypical Dose

2 mg/day SC

watchEffect Window

4-26 weeks for measurable VAT change

lockCompliance

WADA PROHIBITED

Overview

Clinical Summary

Tesamorelin is a prescription GHRH analog used in HIV-associated lipodystrophy. It is used to reduce visceral adipose tissue and improve certain metabolic markers by increasing growth hormone and IGF-1 signaling.

Controlled trials show reduced visceral fat and improvements in triglycerides in HIV-associated lipodystrophy. IGF-1 increases and quality-of-life measures can improve in treated populations. Minority research explores reductions in liver fat in NAFLD contexts, with emerging evidence. Benefits depend on indication and monitoring, since glucose metabolism changes and other adverse effects can occur.

Stimulates endogenous GH release and IGF-1 with downstream visceral fat redistribution in HIV-associated lipodystrophy.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Visceral adipose tissue reduction
  • Liver fat reduction

Secondary Outcomes

  • Body image distress
  • Waist/trunk fat change
  • Metabolic safety markers

Safety

Contraindications and Interactions

Contraindications

  • Uncontrolled diabetes
  • Active malignancy
  • Pregnancy/lactation

Side effects

  • Arthralgia
  • Myalgia
  • Injection-site reactions
  • Paresthesia

Interactions

  • Diabetes medications
  • Other GH/IGF modifiers

Avoid if

  • Healthy population use
  • Unsupervised self-prescribing

Evidence

Study-level References

tesamorelin-SRC-001Randomized, double-blind, placebo-controlled trial
Sourceopen_in_new

https://pubmed.ncbi.nlm.nih.gov/25038357/ (PMID: 25038357)

Population: HIV-infected adults with abdominal fat accumulation

Dose protocol: 2 mg daily SC for 6 months

Key findings: VAT -34 cm2 vs +8 cm2 placebo (difference -42 cm2). Liver fat improved by -2.9% median net.

Notes: Strongest early RCT for primary VAT outcome.

Paper content

VAT -34 cm2 vs +8 cm2 placebo (difference -42 cm2); liver fat improved by -2.9% median net.

tesamorelin-SRC-002Randomized, double-blind, placebo-controlled trial with extension
Sourceopen_in_new

https://pubmed.ncbi.nlm.nih.gov/20101189/

Population: HIV-infected patients with lipodystrophy

Dose protocol: 2 mg daily, 26 weeks then extension to 52 weeks

Key findings: 26-week VAT change ~-10.9% vs -0.6% placebo. Improved body image distress and no major glucose signal.

Notes: Benefit attenuated after discontinuation in long-term follow-up.

Paper content

26-week VAT change ~-10.9% vs -0.6% placebo; improved body image distress and no major glucose signal.

tesamorelin-SRC-003Review
Sourceopen_in_new

https://pubmed.ncbi.nlm.nih.gov/41545261/ (secondary outcome summary)

Population: HIV cohorts

Dose protocol: 2 mg daily in trial arms

Key findings: Pooled VAT reduction MD -27.71 cm2 and hepatic fat reduction MD -4.28%.

Notes: Good consistency on VAT and hepatic fat. Longer-term safety still needs monitoring.

Paper content

BMI and broad body fat mass changes were not consistently significant.

tesamorelin-SRC-004Review
Sourceopen_in_new

https://pubmed.ncbi.nlm.nih.gov/41545261/ (secondary outcome summary)

Population: HIV cohorts

Dose protocol: 2 mg daily in available trials

Key findings: BMI and broad body fat mass changes were not consistently significant.

Notes: Supports population-specific use, not general weight-loss claims.

Paper content

BMI and broad body fat mass changes were not consistently significant.

tesamorelin-SRC-005Phase 2 randomized trial.
Sourceopen_in_new

Ellis RJ, Vaida F, Hu K, Dube M, Henry B, Chow F, Heaton RK, Lee D, Sattler F. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis. 2025;231(5):1230-1238. doi:10.1093/infdis/jiaf012. PMID:39813152.

Population: Virally suppressed adults with HIV and abdominal obesity.

Dose protocol: 2 mg daily SC for 6 months versus standard care

Key findings: Trend toward neurocognitive improvement (P = .060) but no significant between-group difference (P = .673). Waist circumference reduced (P = .015). Cognitive benefit not established.

Notes: Underpowered for cognitive endpoint. Confirms VAT reduction but does not extend benefit to cognition.

Paper content

This phase 2 randomized trial tested whether tesamorelin could improve cognitive function in 73 virally suppressed adults with HIV and abdominal obesity. After 6 months, the tesamorelin group showed a trend toward improved neurocognitive performance (P = .060), but between-group differences were not statistically significant (P = .673). Tesamorelin did reduce waist circumference significantly compared to standard care (P = .015), and IGF-1 levels increased, but these body composition changes did not correlate with cognitive improvements. The study was underpowered and lacked a placebo injection arm, limiting interpretation. The result does not support a cognitive benefit from short-term visceral fat reduction with tesamorelin.

tesamorelin-SRC-006Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_new

Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M, Stanley TL, Hadigan CM, Grinspoon SK, Erlandson KM, Fourman LT. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. doi:10.1097/QAD.0000000000003965. PMID:38905488.

Population: Adults with HIV on integrase inhibitor-based antiretroviral regimens with abdominal fat accumulation.

Dose protocol: 2 mg daily SC for 12 months, double-blind, placebo-controlled

Key findings: First dedicated trial in people with HIV on integrase inhibitors. Significant visceral and hepatic fat reduction with no differential hyperglycemia risk.

Notes: Fills an important evidence gap for the contemporary INSTI-treated HIV population.

Paper content

This randomized double-blind trial is the first dedicated evaluation of tesamorelin in people with HIV on integrase inhibitor-based antiretroviral therapy, a drug class that was not available during the original phase III program. Among 31 completers, tesamorelin significantly reduced visceral fat and hepatic fat while improving fat distribution. Importantly, there was no differential hyperglycemia risk despite the metabolic complications associated with integrase inhibitors. The small sample size (38 randomized, 31 completers) limits generalizability, but the trial fills an important evidence gap by confirming that tesamorelin retains efficacy and safety in the contemporary INSTI-treated HIV population.

Guides

Setup

Help